# US 2014/0155497 A1 · Heparosan-based biomaterials and coatings and methods of production and use thereof > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0155497 A1 - Document ID: US20140155497A1 - Status: Published application - Kind: A1 - Application number: 14/060,077 - Filed: 2013-10-22 - Published: 2014-06-05 - Earliest claimed: 2001-05-08 - Assignees: The Board of Regents of the University of Oklahoma - Applicants: The Board of Regents of the University of Oklahoma - Inventors: Paul L. DeAngelis - Web page: https://patentgrep.com/patent/US20140155497A1 ## CPC - C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof} - A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 31/726: Glycosaminoglycans, i.e. mucopolysaccharides (chondroitin sulfate, dermatan sulfate A61K31/737) - A61K 47/02: Inorganic compounds - A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin - A61L 31/10: Macromolecular materials - C07H 5/04: to nitrogen - A61L 2420/02: Methods for coating medical devices - C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K) - C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13) ## Abstract Biomaterial compositions that include an isolated heparosan polymer are disclosed, as well as kits containing such biomaterial compositions and methods of producing and using such biomaterial compositions. ## Claims ### Claim 1 A biomaterial composition, the composition comprising: an isolated heparosan polymer, wherein the isolated heparosan polymer is biocompatible with a mammalian patient and is represented by the structure (-GlcUA-β1,4-GlcNAc-α1,4-)n, and wherein at least one of: n is about 1,000; and the molecular weight of the isolated heparosan polymer is in a range of from about 0.5 MDa to about 4.5 MDa. ### Claim 2 (depends on 1) The biomaterial composition of claim 1, wherein the heparosan polymer is linear. ### Claim 3 (depends on 1) The biomaterial composition of claim 1, wherein the heparosan polymer is crosslinked. ### Claim 4 (depends on 1) The biomaterial composition of claim 1, wherein the composition is in a gel, semi-solid, and/or particulate state. ### Claim 5 (depends on 1) The biomaterial composition of claim 1, wherein the composition is in a liquid state. ### Claim 6 (depends on 1) The biomaterial composition of claim 1, wherein the composition is injectable and/or implantable. ### Claim 7 (depends on 1) The biomaterial composition of claim 1, wherein the composition is substantially not susceptible to hyaluronidases and/or heparanases and thereby is not substantially degraded in vivo. ### Claim 8 A biomaterial composition, the composition comprising: an isolated derivatized heparosan polymer, wherein the isolated derivatized heparosan polymer is biocompatible with a mammalian patient and is represented by the structure (-GlcUA-β1,4-GlcNAc-α1,4-)n, wherein n is a positive integer greater than or equal to 1, and wherein the derivatized heparosan polymer is not found in nature. ### Claim 9 (depends on 8) The method of claim 8, wherein the heparosan polymer is derivatized by crosslinking at least a portion thereof. ### Claim 10 (depends on 8) The biomaterial composition of claim 8, wherein n is greater than 10. ### Claim 11 (depends on 8) The biomaterial composition of claim 8, wherein the composition is in a gel, semi-solid, and/or particulate state. ### Claim 12 (depends on 8) The biomaterial composition of claim 8, wherein the composition is in a liquid state. ### Claim 13 (depends on 8) The biomaterial composition of claim 8, wherein the composition is injectable and/or implantable. ### Claim 14 (depends on 8) The biomaterial composition of claim 8, wherein the composition is substantially not susceptible to hyaluronidases and/or heparanases and thereby is not substantially degraded in vivo. ### Claim 15 A biomaterial composition, the composition comprising: an isolated heparosan polymer, wherein the isolated heparosan polymer is biocompatible with a mammalian patient, and wherein the isolated heparosan polymer is represented by the structure (-GlcUA-β1,4-GlcNAc-α1,4-)n, wherein n is a positive integer greater than or equal to 1; a substrate; and wherein the isolated heparosan polymer is attached to the substrate. ### Claim 16 (depends on 15) The biomaterial composition of claim 15, wherein the isolated heparosan polymer is covalently attached to the substrate. ### Claim 17 (depends on 15) The biomaterial composition of claim 15, wherein the isolated heparosan polymer is non-covalently attached to the substrate. ### Claim 18 (depends on 15) The biomaterial composition of claim 15, wherein the substrate is selected from the group consisting of silica, silicon, semiconductors, glass, polymers, organic compounds, inorganic compounds, metals and combinations thereof. ### Claim 19 (depends on 18) The biomaterial composition of claim 18, wherein at least a portion of the substrate is a metal selected from the group consisting of gold, copper, stainless steel, nickel, aluminum, titanium, thermosensitive alloys and combinations thereof. ### Claim 20 (depends on 15) The biomaterial composition of claim 15, wherein at least one of: (a) n is greater than 10; (b) n is about 1,000; (c) the heparosan polymer is linear; (d) the heparosan polymer is crosslinked; and (e) the composition is substantially not susceptible to hyaluronidases and/or heparanases and thereby is not substantially degraded in vivo. ### Claim at position 21 21-28. (canceled)